A Trial of CM-AT in Children With Autism- Open Label Extension Study

PHASE3CompletedINTERVENTIONAL
Enrollment

165

Participants

Timeline

Start Date

January 31, 2010

Primary Completion Date

February 29, 2016

Study Completion Date

February 29, 2016

Conditions
Autism
Interventions
DRUG

CM-AT

Single unit dose powder of active substance (CM-AT) administered 3 times per day for 90 days

Trial Locations (19)

10029

Mount Sinai School of Medicine, Manhattan

15260

Universtiy of Pittsburgh, Pittsburgh

17033

Hershey Medical Center, Hershey

19124

Drexel University, Philadelphia

27514

University of North Carolina, Chapel Hill, Chapel Hill

30080

Institute for Behavioral Medicine, Smyrna

32763

Lake Mary Pediatrics, Orange City

43210

Ohio State University, Columbus

60169

Alexian Brothers Center for Psychiatric Research, Hoffman Estates

71103

Louisiana State University, Shreveport

73117

Oklahoma State University, Child Study Center, Oklahoma City

77054

University of Texas, Houston, Houston

84015

Ericksen Research & Development, Clinton

85006

Southwest Autism Research and Resource Center, Phoenix

92701

Neuropsychiatric Research Center of Orange County, Santa Ana

94143

University of California, San Francisco, San Francisco

95817

University of California, Davis, M.I.N.D. Institute, Sacramento

97030

Cyn3rgy Research Center, Gresham

08901

Saint Peter's University Hospital, New Brunswick

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Curemark

INDUSTRY

NCT00912691 - A Trial of CM-AT in Children With Autism- Open Label Extension Study | Biotech Hunter | Biotech Hunter